Terapia celular con células madre derivadas del tejido adulto en un modelo murino de ictus mediante oclusión de la arteria cerebral media
- Autores: Silvia Mora Lee
- Directores de la Tesis: Felipe Prósper Cardoso (dir. tes.)
- Lectura: En la Universidad de Navarra ( España ) en 2011
- Idioma: español
- Tribunal Calificador de la Tesis: Jose Manuel García Verdugo (presid.), Manuel María Mazo Vega (secret.), Josune Orbe (voc.), Jaime Gallego Culleré (voc.), María Salomé Sirerol Piquer (voc.)
- Materias:
- Texto completo no disponible (Saber más ...)
- Resumen
Stroke models are essential tools in experimental stroke. Although several models of stroke have been developed in a variety of animals, with the development of transgenic mice there is the need to develop a reliable and reproducible stroke model mice, which mimics as close as possible human stroke.
Stroke represents an attractive target of stem cell therapy and although different types of cells have been employed in animal models, a direct comparison between cells sources has not been performed.
The aim of our study was to compare the effect of human multipotent stem cells (hMAPCs) and human mesenchymal stem cells (hMSCs) and to determine the mechanism involved in tissue repair.
BALB/Ca-RAG2-/- c/-ɤc/- mice were subjected to cauterization or thrombosis stroke and sacrificed at different time points (48 hr, 1 wk, 2 wk and 4wk) after stroke. Mice received BrdU to estimated activation of cell proliferation in the SVZ. Brains were processed for immunohistochemical an EM.
BALB/Ca-RAG2-/- c/-ɤc/- mice were subjected to FeCl3 thrombosis stroke model were intracranially injected with 2 x 105 hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days.
Our results provide an exhaustive analysis of the histophatological changes that occur after stroke in the ischemic boundary zone, which are of key importance for the final stroke outcome.
Transplantation of hMSCs and hMAPCs produced greater brain integrity preservation as determined by the decreased loss of tissue mediated by several mechanisms.
Interestingly, these neuroprotective effects were more pronounced in the group of animals treated with hMAPCs in comparison with hMSCs. Our results establish cell therapy with hMAPCs in comparison with hMSCs. Our results establish cell therapy with hMAPCs and hMSCs as a promising strategy for treatment of stroke.
